In Sam Bankman Fried’s first live interview since stepping down as CEO of FTX, with the New York Times’ Andrew Ross Sorkin at the DealBook summit, he was asked about his—and his colleagues’—drug use amid the crypto exchange’s shockingly abrupt collapse this month.
“Can you just speak to the idea of this company that, at least from the public perspective, seemed like a regulated company or something that was very focused on compliance…but it seems like when you read the stories, it sounds like a bunch of kids who were on Adderall having a sleepover party,” Sorkin asked Bankman-Fried on Wednesday.
